KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Clinical trial NCT04265534 · TERMINATED

Trial details

NCT number: NCT04265534
Sponsor: Calithera Biosciences, Inc
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer Non-squamous Non-small-cell Lung Cancer Non-Squamous Non-Small Cell Neoplasm of Lung KEAP1 Gene Mutation NRF2 Gene Mutation NFE2L2 Gene Mutation

Start date: 2020-07-24
Primary completion: 2021-11-05
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.